Endothelial hyperactivation of mutant MAP3K3 induces cerebral cavernous malformation enhanced by PIK3CA GOF mutation
Authors:
- 31 January 2023
- journal article
- research article
- Published by Springer Nature in Angiogenesis
- Vol. 26 (2) , 295-312
Abstract
Cerebral cavernous malformations (CCMs) refer to a common vascular abnormality that affects up to 0.5% of the population. A somatic gain-of-function mutation in MAP3K3 (p.I441M) was recently reported in sporadic CCMs, frequently accompanied by somatic activating PIK3CA mutations in diseased endothelium. However, the molecular mechanisms of these driver genes remain elusive. In this study, we performed whole-exome sequencing and droplet digital polymerase chain reaction to analyze CCM lesions and the matched blood from sporadic patients. 44 of 94 cases harbored mutations in KRIT1/CCM2 or MAP3K3, of which 75% were accompanied by PIK3CA mutations (P = 0.006). AAV-BR1-mediated brain endothelial-specific MAP3K3I441M overexpression induced CCM-like lesions throughout the brain and spinal cord in adolescent mice. Interestingly, over half of lesions disappeared at adulthood. Single-cell RNA sequencing found significant enrichment of the apoptosis pathway in a subset of brain endothelial cells in MAP3K3I441M mice compared to controls. We then demonstrated that MAP3K3I441M overexpression activated p38 signaling that is associated with the apoptosis of endothelial cells in vitro and in vivo. In contrast, the mice simultaneously overexpressing PIK3CA and MAP3K3 mutations had an increased number of CCM-like lesions and maintained these lesions for a longer time compared to those with only MAP3K3I441M. Further in vitro and in vivo experiments showed that activating PI3K signaling increased proliferation and alleviated apoptosis of endothelial cells. By using AAV-BR1, we found that MAP3K3I441M mutation can provoke CCM-like lesions in mice and the activation of PI3K signaling significantly enhances and maintains these lesions, providing a preclinical model for the further mechanistic and therapeutic study of CCMs.Keywords
Funding Information
- Hong Kong RGC Fund (16102522, C6021-19EF)
- Hong Kong ITC Fund (ITCPD/17-9)
- Department of Science and Technology of Guangdong Province (2020A0505090007)
- NSFC General Program (82171267)
- Genomics Platform Construction for Chinese Major Brain Disease-AVM (PXM2019_026280_000002-AVM)
- Beijing Advanced Innovation Center for Big Data-based Precision Medicine (PXM2020_014226_000066)
This publication has 42 references indexed in Scilit:
- Developmental timing of CCM2 loss influences cerebral cavernous malformations in miceJournal of Experimental Medicine, 2011
- Retro-orbital injections in miceLab Animal, 2011
- A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human diseaseHuman Molecular Genetics, 2010
- Phosphatase and tensin homolog in cerebral cavernous malformation: a potential role in pathological angiogenesisJournal of Neurosurgery, 2009
- Hemorrhage From Cavernous Malformations of the BrainStroke, 2008
- p38 MAPK plays an essential role in apoptosis induced by photoactivation of a novel ethylene glycol porphyrin derivativeOncogene, 2007
- Loss of p53 Sensitizes Mice with a Mutation in Ccm1 (KRIT1) to Development of Cerebral Vascular MalformationsThe American Journal of Pathology, 2004
- Mutations in a Gene Encoding a Novel Protein Containing a Phosphotyrosine-Binding Domain Cause Type 2 Cerebral Cavernous MalformationsThe American Journal of Human Genetics, 2003
- The Phosphoinositide 3-Kinase PathwayScience, 2002
- Ultrastructural and immunocytochemical evidence that an incompetent blood-brain barrier is related to the pathophysiology of cavernous malformationsJournal of Neurology, Neurosurgery & Psychiatry, 2001